Nanosonics Secures First US FDA Clearance for Endoscope Technology
MT Newswires Live
Mar 09
Nanosonics (ASX:NAN) secured its first 510(k) clearance from the US Food and Drug Administration (FDA) for the first round of expanded endoscope indications for its CORIS system, according to a Monday filing with the Australian bourse.
The clearance allows for the expansion of the system across a wider range of endoscope indications and the submission of a second 510(k) to further extend coverage, the filing said.
Controlled market release has begun in the UK, with Australia soon to follow, per the filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.